Larotrectinib shows marked responses with NTRK gene fusions,...
In an analysis of three clinical trials, the targeted therapy larotrectinib resulted in a 79% overall response rate and median overall...
Genomic study of brain metastases sheds light on unique...
A deep sequencing study of brain metastases from MD Anderson revealed many similarities but also distinct differences relative to the...
Phase I clinical trial shows WNT974 in combination with...
An MD Anderson Phase I clinical trial demonstrated that a combination therapy using WNT974, a drug that targets the WNT pathway in...
Study shows naproxen promotes immune activation in Lynch syndrome...
A Phase I chemoprevention clinical trial led by MD Anderson researchers found that naproxen, an over-the-counter anti-inflammatory...
AACR: Ovarian cancer clinical trial shows effects, safety...
Results from a clinical trial led by MD Anderson researchers showed that combining the immunotherapy checkpoint inhibitor drug...
Ovarian cancer analysis identifies potential treatment...
MD Anderson researchers have identified potential biomarkers for the response of high-grade serous ovarian cancers (HGSC) to surgical...